REFERENCES
1. Li P, Ding Z, Feng Y, et al. Global, regional, and national burden of hepatocellular carcinoma and contribution of nine modifiable risk factors across 185 countries/territories in 2022. Sci Bull. 2026;71:838-49.
2. Chong B, Kong G, Shankar K, et al. The global syndemic of metabolic diseases in the young adult population: a consortium of trends and projections from the Global Burden of Disease 2000-2019. Metabolism. 2023;141:155402.
3. Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851-61.
4. Na BG, Han SS, Cho YA, et al. Nutritional status of patients with cancer: a prospective cohort study of 1,588 hospitalized patients. Nutr Cancer. 2018;70:1228-36.
5. Kim Y, Kim SR, Kim K, Yu SJ. Demographic, clinical and psychological predictors of malnutrition among people with liver cancer. Eur J Oncol Nurs. 2024;68:102497.
6. Rios TC, de Oliveira LPM, da Costa MLV, et al. A poorer nutritional status impacts quality of life in a sample population of elderly cancer patients. Health Qual Life Outcomes. 2021;19:90.
7. da Silva GD, Batista AVA, Costa MCRA, Dos Santos ACO. The ability of GLIM and MNA-FF to diagnose malnutrition and predict sarcopenia and frailty in hospitalized adults over 60 years of age. Front Nutr. 2024;11:1456091.
8. Xu Y, Hao X, Ren Y, et al. Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma. Front Oncol. 2022;12:1063423.
9. Lequoy M, Gigante E, Couty JP, Desbois-Mouthon C. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms. Horm Mol Biol Clin Investig. 2020;41:1-44.
10. Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer. 2015;15:484-98.
11. Ruan X, Nakyeyune R, Shao Y, et al. Nutritional screening tools for adult cancer patients: a hierarchical Bayesian latent-class meta-analysis. Clin Nutr. 2021;40:1733-43.
12. Xie H, Yuan K, Ruan G, et al. Improving the assessment of malnutrition in cancer: Using systemic inflammation markers as a supplement to the inflammation items of the GLIM criteria. Clin Nutr. 2023;42:2036-44.
13. Gort-van Dijk D, Weerink LBM, Milovanovic M, et al. Bioelectrical impedance analysis and mid-upper arm muscle circumference can be used to detect low muscle mass in clinical practice. Nutrients. 2021;13:2350.
14. Kotoh Y, Saeki I, Yamasaki T, et al. Albumin-bilirubin score as a useful predictor of energy malnutrition in patients with hepatocellular carcinoma. Clin Nutr. 2021;40:3585-91.
15. Bischoff SC, Bernal W, Dasarathy S, et al. ESPEN practical guideline: clinical nutrition in liver disease. Clin Nutr. 2020;39:3533-62.
16. Trujillo EB, Kadakia KC, Thomson C, et al. Malnutrition risk screening in adult oncology outpatients: an ASPEN systematic review and clinical recommendations. JPEN J Parenter Enteral Nutr. 2024;48:874-94.
17. Ge Y, Shi H, shen X. Aiww: a new nutrition screening tool for the oncologic population. Clinical Nutrition ESPEN. 2023;54:541.
18. Wiegert EVM, Padilha PC, Peres WAF. Performance of patient-generated subjective global assessment (PG-SGA) in patients with advanced cancer in palliative care. Nutr Clin Pract. 2017;32:675-81.
19. Zhang KP, Tang M, Fu ZM, et al. Global Leadership Initiative on Malnutrition criteria as a nutrition assessment tool for patients with cancer. Nutrition. 2021;91-92:111379.
20. Rosnes KS, Henriksen C, Høidalen A, Paur I. Agreement between the GLIM criteria and PG-SGA in a mixed patient population at a nutrition outpatient clinic. Clin Nutr. 2021;40:5030-7.
21. Sobrini P, Sánchez-Castellano C, Cruz-Jentoft AJ. MNA-SF as a screening tool for malnutrition diagnosed with the glim criteria in older persons with cancer. Eur Geriatr Med. 2021;12:653-6.
22. McFarlane M, Hammond C, Roper T, et al. Comparing assessment tools for detecting undernutrition in patients with liver cirrhosis. Clin Nutr ESPEN. 2018;23:156-61.
23. Borhofen SM, Gerner C, Lehmann J, et al. The royal free hospital-nutritional prioritizing tool is an independent predictor of deterioration of liver function and survival in cirrhosis. Dig Dis Sci. 2016;61:1735-43.
24. Georgiou A, Papatheodoridis GV, Alexopoulou A, et al. Evaluation of the effectiveness of eight screening tools in detecting risk of malnutrition in cirrhotic patients: the KIRRHOS study. Br J Nutr. 2019;122:1368-76.
25. Xu J, Li J, Chen H, et al. Prevalence and prognostic significance of malnutrition in patients with non-alcoholic fatty liver disease (NAFLD). Int J Vitam Nutr Res. 2024;95:26099.
26. Ruiz-Margáin A, Román-Calleja BM, Moreno-Guillén P, et al. Nutritional therapy for hepatocellular carcinoma. World J Gastrointest Oncol. 2021;13:1440-52.
27. Topan MM, Sporea I, Dănilă M, et al. Comparison of different nutritional assessment tools in detecting malnutrition and sarcopenia among cirrhotic patients. Diagnostics. 2022;12:893.
28. Sguanci M, Palomares SM, Cangelosi G, et al. Artificial intelligence in the management of malnutrition in cancer patients: a systematic review. Adv Nutr. 2025;16:100438.
29. Zhang Z, Wan Z, Zhu Y, Zhang L, Zhang L, Wan H. Prevalence of malnutrition comparing NRS2002, MUST, and PG-SGA with the GLIM criteria in adults with cancer: a multi-center study. Nutrition. 2021;83:111072.
30. Zhang P, Wang Q, Zhu M, Li P, Wang Y. Differences in nutritional risk assessment between NRS2002, RFH-NPT and LDUST in cirrhotic patients. Sci Rep. 2023;13:3306.
31. Rajab N, Abdul Hamid SB, Mohd Said AH, Md Isa KA. Validation of nutrition screening tool: royal free hospital nutritional prioritizing tool (RFH-NPT) for chronic liver disease patients. MJMHS. 2023;19:130-7.
32. Wang R, Huang L, Xu M, Yu X, Wang H. Comparison of different nutritional screening tools in nutritional screening of patients with cirrhosis: a cross-sectional observational study. Heliyon. 2024;10:e30339.
33. Liu CH, Zeng QM, Kim W, et al. Sarcopenia and MASLD: novel insights and the future. Nat Rev Endocrinol. 2026;22:139-52.
34. Kim G, Lee SE, Lee YB, et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study. Hepatology. 2018;68:1755-68.
35. Petermann-Rocha F, Gray SR, Forrest E, et al. Associations of muscle mass and grip strength with severe NAFLD: a prospective study of 333,295 UK Biobank participants. J Hepatol. 2022;76:1021-9.
36. Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology. 2019;69:107-20.
37. Selvam S, Vairappan B. Tight junction proteins: gatekeepers turned facilitators in the pathogenesis of gastric adenocarcinoma. World J Gastrointest Oncol. 2026;18:114040.
38. Wang X, Li MM, Niu Y, et al. Serum zonulin in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Dis Markers. 2019;2019:5945721.
39. Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E. The role of the microbiome in NAFLD and NASH. EMBO Mol Med. 2019;11:e9302.
40. Dong YQ, Lu CW, Zhang L, Yang J, Hameed W, Chen W. Toll-like receptor 4 signaling promotes invasion of hepatocellular carcinoma cells through MKK4/JNK pathway. Mol Immunol. 2015;68:671-83.
41. Che Z, Xue W, Zhao X, Hu C, Tian Y. Regulatory role and biomarker potential of gut microbiota metabolites in the progression of metabolic dysfunction-associated steatotic liver disease to hepatocellular carcinoma. Clin Transl Gastroenterol. 2025;16:e00914.
42. Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation. 2019;103:e1-13.
43. Chang KV, Wu WT, Chen YH, et al. Enhanced serum levels of tumor necrosis factor-α, interleukin-1β, and -6 in sarcopenia: alleviation through exercise and nutrition intervention. Aging. 2023;15:13471-85.
44. Choi K, Jang HY, Ahn JM, et al. The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma. Clin Mol Hepatol. 2020;26:492-505.
45. Ding J, Yang G, Sun W, et al. Association of interleukin-6 with sarcopenia and its components in older adults: a systematic review and meta-analysis of cross-sectional studies. Ann Med. 2024;56:2384664.
46. Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234-48.
47. Jaśkiewicz A, Domoradzki T, Pająk B. Targeting the JAK2/STAT3 pathway-can we compare it to the two faces of the god janus? Int J Mol Sci 2020;21:8261.
48. Sciorati C, Gamberale R, Monno A, et al. Pharmacological blockade of TNFα prevents sarcopenia and prolongs survival in aging mice. Aging. 2020;12:23497-508.
49. Yi X, Tao J, Qian Y, et al. Morroniside ameliorates inflammatory skeletal muscle atrophy via inhibiting canonical and non-canonical NF-κB and regulating protein synthesis/degradation. Front Pharmacol. 2022;13:1056460.
50. Li J, Yi X, Yao Z, Chakkalakal JV, Xing L, Boyce BF. TNF receptor-associated factor 6 mediates TNFα-induced skeletal muscle atrophy in mice during aging. J Bone Miner Res. 2020;35:1535-48.
51. Lahiri S, Kim H, Garcia-Perez I, et al. The gut microbiota influences skeletal muscle mass and function in mice. Sci Transl Med. 2019;11:eaan5662.
52. Li L, Lian P, Dong W, et al. Restoring muribaculum intestinale-derived butyrate mitigates skeletal muscle loss in cancer cachexia. J Cachexia Sarcopenia Muscle. 2025;16:e70140.
53. Yoshida H, Ishii M, Akagawa M. Propionate suppresses hepatic gluconeogenesis via GPR43/AMPK signaling pathway. Arch Biochem Biophys. 2019;672:108057.
54. Asaoka D, Toda K, Yoshimoto S, et al. Sex-specific associations of gut microbiota composition with sarcopenia defined by the Asian working group for sarcopenia 2019 consensus in older outpatients: prospective cross-sectional study in Japan. Nutrients. 2025;17:1746.
55. Liu C, Cheung WH, Li J, et al. Understanding the gut microbiota and sarcopenia: a systematic review. J Cachexia Sarcopenia Muscle. 2021;12:1393-407.
57. Ippolito L, Morandi A, Giannoni E, Chiarugi P. Lactate: A metabolic driver in the tumour landscape. Trends Biochem Sci. 2019;44:153-66.
58. Lin J, Rao D, Zhang M, Gao Q. Metabolic reprogramming in the tumor microenvironment of liver cancer. J Hematol Oncol. 2024;17:6.
59. Órdenes P, Villar PS, Tarifeño-Saldivia E, et al. Lactate activates hypothalamic POMC neurons by intercellular signaling. Sci Rep. 2021;11:21644.
60. Liu X, Li S, Cui Q, et al. Activation of GPR81 by lactate drives tumour-induced cachexia. Nat Metab. 2024;6:708-23.
61. Davis MP, Dreicer R, Walsh D, Lagman R, LeGrand SB. Appetite and cancer-associated anorexia: a review. J Clin Oncol. 2004;22:1510-7.
62. Han J, Liang X, Guo Y, Wu X, Li Z, Hong T. Agouti-related protein as the glucose signaling sensor in the central melanocortin circuits in regulating fish food intake. Front Endocrinol. 2022;13:1010472.
63. Yeom E, Yu K. Understanding the molecular basis of anorexia and tissue wasting in cancer cachexia. Exp Mol Med. 2022;54:426-32.
64. Laird BJ, McMillan D, Skipworth RJE, et al. The emerging role of interleukin 1β (IL-1β) in cancer cachexia. Inflammation. 2021;44:1223-8.
65. Braun TP, Zhu X, Szumowski M, et al. Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis. J Exp Med. 2011;208:2449-63.
66. Campos CA, Bowen AJ, Han S, Wisse BE, Palmiter RD, Schwartz MW. Cancer-induced anorexia and malaise are mediated by CGRP neurons in the parabrachial nucleus. Nat Neurosci. 2017;20:934-42.
67. Roman CW, Derkach VA, Palmiter RD. Genetically and functionally defined NTS to PBN brain circuits mediating anorexia. Nat Commun. 2016;7:11905.
68. Olson B, Zhu X, Norgard MA, et al. Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia. Nat Commun. 2021;12:2057.
69. Li X, Holtrop T, Jansen FAC, et al. Lipopolysaccharide-induced hypothalamic inflammation in cancer cachexia-anorexia is amplified by tumour-derived prostaglandin E2. J Cachexia Sarcopenia Muscle. 2022;13:3014-27.
70. Cao HM, Ye XP, Ma JH, et al. Mimecan, a hormone abundantly expressed in adipose tissue, reduced food intake independently of leptin signaling. EBioMedicine. 2015;2:1718-24.
71. Borner T, Liberini CG, Lutz TA, Riediger T. Brainstem GLP-1 signalling contributes to cancer anorexia-cachexia syndrome in the rat. Neuropharmacology. 2018;131:282-90.
72. Liu J, Jing C, Guo Y, et al. The central signaling pathways related to metabolism-regulating hormones of the gut-brain axis: a review. J Transl Med. 2025;23:648.
73. Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61:364-71.
74. Nøhr MK, Egerod KL, Christiansen SH, et al. Expression of the short chain fatty acid receptor GPR41/FFAR3 in autonomic and somatic sensory ganglia. Neuroscience. 2015;290:126-37.
75. Martin CR, Osadchiy V, Kalani A, Mayer EA. The brain-gut-microbiome axis. Cell Mol Gastroenterol Hepatol. 2018;6:133-48.
76. Sanchez JG, Enriquez JR, Wells JM. Enteroendocrine cell differentiation and function in the intestine. Curr Opin Endocrinol Diabetes Obes. 2022;29:169-76.
77. Duran M, Willis JR, Dalvi N, Fokakis Z, Virkus SA, Hardaway JA. Integration of glucagon-like peptide 1 receptor actions through the central amygdala. Endocrinology. 2025;166:bqaf019.
78. Al-Amouri FM, Badrasawi M. Taste alteration and its relationship with nutritional status among cancer patients receiving chemotherapy, cross-sectional study. PLoS One. 2024;19:e0302990.
79. Fons A, Oreskovich D, Prioult G, von der Weid B, Lerea-Antes J. Taste alterations in patients with cancer: an overview and recommendations for future research. Support Care Cancer. 2025;33:784.
80. Juthani R, Malalur P, Manne A, Mittra A. The combined use of lenvatinib and locoregional therapies for the management of hepatocellular carcinoma. Cancers. 2025;17:1572.
81. Hustad KS, Koteng LH, Urrizola A, et al. ; MyPath consortium. Practical cancer nutrition, from guidelines to clinical practice: a digital solution to patient-centred care. ESMO Open. 2025;10:104529.
82. Vaughn BP, Rank KM, Khoruts A. Fecal microbiota transplantation: current status in treatment of GI and liver disease. Clin Gastroenterol Hepatol. 2019;17:353-61.
83. Ademe M. Benefits of fecal microbiota transplantation: a comprehensive review. J Infect Dev Ctries. 2020;14:1074-80.
84. Gu C, Sha G, Zeng B, Cao H, Cao Y, Tang D. Therapeutic potential of fecal microbiota transplantation in colorectal cancer based on gut microbiota regulation: from pathogenesis to efficacy. Ther Adv Gastroenterol. 2025;18:17562848251327167.
85. Lim MY, Hong S, Nam YD. Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review. Front Immunol. 2024;15:1512683.
86. Karimi M, Shirsalimi N, Hashempour Z, et al. Safety and efficacy of fecal microbiota transplantation (FMT) as a modern adjuvant therapy in various diseases and disorders: a comprehensive literature review. Front Immunol. 2024;15:1439176.
87. Yong D. Screening for potential infections in fecal microbiota transplantation guidelines and an experience of microbiota bank operation in Korea: a narrative review. Ann Clin Microbiol. 2024;27:11-7.
88. Fuhri Snethlage CM, Nieuwdorp M, Hanssen NMJ. Faecal microbiota transplantation in endocrine diseases and obesity. Best Pract Res Clin Endocrinol Metab. 2021;35:101483.
89. Elghannam MT, Hassanien MH, Ameen YA, et al. Gut microbiome and gastric cancer: microbial interactions and therapeutic potential. Gut Pathog. 2025;17:56.
90. Kao D, Roach B, Silva M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent clostridium difficile infection: a randomized clinical trial. JAMA. 2017;318:1985-93.
91. Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the literature. J Hosp Infect. 2016;92:117-27.
92. Yadegar A, Bar-Yoseph H, Monaghan TM, et al. Fecal microbiota transplantation: current challenges and future landscapes. Clin Microbiol Rev. 2024;37:e0006022.
93. Xiao Y, Angulo MT, Lao S, Weiss ST, Liu YY. An ecological framework to understand the efficacy of fecal microbiota transplantation. Nat Commun. 2020;11:3329.
94. Swanson KS, Gibson GR, Hutkins R, et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol. 2020;17:687-701.
95. Han SH, Suk KT, Kim DJ, et al. Effects of probiotics (cultured Lactobacillus subtilis/Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study. Eur J Gastroenterol Hepatol. 2015;27:1300-6.
96. Zhao Z, Chen L, Zhao Y, et al. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation. Appl Microbiol Biotechnol. 2020;104:5273-82.
97. Manzhalii E, Virchenko O, Falalyeyeva T, Beregova T, Stremmel W. Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: a pilot trial. J Dig Dis. 2017;18:698-703.
98. Sepideh A, Karim P, Hossein A, et al. Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial. J Am Coll Nutr. 2016;35:500-5.
99. Min S, Than N, Shin YC, et al. Live probiotic bacteria administered in a pathomimetic Leaky Gut Chip ameliorate impaired epithelial barrier and mucosal inflammation. Sci Rep. 2022;12:22641.
100. Ye Z, Tan Q, Woltemate S, et al. Escherichia coli nissle improves short-chain fatty acid absorption and barrier function in a mouse model for chronic inflammatory diarrhea. Inflamm Bowel Dis. 2025;31:1109-20.
101. Roobab U, Batool Z, Manzoor MF, Shabbir MA, Khan MR, Aadil RM. Sources, formulations, advanced delivery and health benefits of probiotics. Current Opinion in Food Science. 2020;32:17-28.
102. Silva DR, Sardi JDCO, Pitangui NDS, Roque SM, Silva ACBD, Rosalen PL. Probiotics as an alternative antimicrobial therapy: current reality and future directions. J Funct Foods. 2020;73:104080.
103. Akbar Z, Zahoor T, Huma N, Jamil A, Ayesha H, Kumar Irudayaraj JM. Electrospun probiotics: an alternative for encapsulation. J Biol Regul Homeost Agents. 2018;32:1551-6.
104. Huang Y, Zhang L, Hu J, Liu H. Improved loading capacity and viability of probiotics encapsulated in alginate hydrogel beads by in situ cultivation method. Foods. 2023;12:2256.
105. Liu Q, Lin C, Yang X, et al. Improved viability of probiotics via microencapsulation in Whey-Protein-Isolate-Octenyl-Succinic-Anhydride-Starch-Complex coacervates. Molecules. 2023;28:5732.
106. Albadran HA, Monteagudo-Mera A, Khutoryanskiy VV, Charalampopoulos D. Development of chitosan-coated agar-gelatin particles for probiotic delivery and targeted release in the gastrointestinal tract. Appl Microbiol Biotechnol. 2020;104:5749-57.
107. Fu Y, Liu L, Zhang J, et al. Reinforcing alginate matrixes by tea polysaccharide conjugates or their stabilized nanoemulsion for probiotics encapsulation: characterization, survival after gastrointestinal digestion and ambient storage. Int J Biol Macromol. 2023;253:126828.
108. Hao R, Chen Z, Wu Y, et al. Improving the survival of Lactobacillus plantarum FZU3013 by phase separated caseinate/alginate gel beads. Int J Biol Macromol. 2024;260:129447.
